215 related articles for article (PubMed ID: 17768034)
1. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2007 Nov; 30(5):415-21. PubMed ID: 17768034
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
3. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Zervos M; Martinez FJ; Amsden GW; Rothermel CD; Treadway G
Int J Antimicrob Agents; 2007 Jan; 29(1):56-61. PubMed ID: 17189096
[TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
6. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis.
Starakis I; Gogos CA; Bassaris H
Int J Antimicrob Agents; 2004 Feb; 23(2):129-37. PubMed ID: 15013037
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin and biofilm production by coagulase-negative staphylococci.
Pérez-Giraldo C; Gonzalez-Velasco C; Sánchez-Silos RM; Hurtado C; Blanco MT; Gómez-García AC
Chemotherapy; 2004 Jun; 50(2):101-4. PubMed ID: 15211086
[TBL] [Abstract][Full Text] [Related]
8. Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics.
Presterl E; Grisold AJ; Reichmann S; Hirschl AM; Georgopoulos A; Graninger W
J Antimicrob Chemother; 2005 Jan; 55(1):45-50. PubMed ID: 15563519
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
12. Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Roveta S; Marchese A; Debbia EA
Chemotherapy; 2008; 54(1):43-9. PubMed ID: 18073470
[TBL] [Abstract][Full Text] [Related]
13. Activity of ciprofloxacin and azithromycin on biofilms produced in vitro by Haemophilus influenzae.
Wang D; Wang Y; Liu YN
Chin Med J (Engl); 2009 Jun; 122(11):1305-10. PubMed ID: 19567142
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey.
Decousser JW; Allouch PY; Courvalin P; Leclercq R;
Int J Antimicrob Agents; 2002 Sep; 20(3):186-95. PubMed ID: 12385697
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of fluoroquinolones on urological infection pathogens within biofilms].
Tets VV; Artemenko NK; Zaslavskaia NV; Tets GV
Urologiia; 2010; (1):13-7. PubMed ID: 20891043
[TBL] [Abstract][Full Text] [Related]
16. Effects of demethylfruticuline A and fruticuline A from Salvia corrugata Vahl. on biofilm production in vitro by multiresistant strains of Staphylococcus aureus, Staphylococcus epidermidis and Enterococcus faecalis.
Schito AM; Piatti G; Stauder M; Bisio A; Giacomelli E; Romussi G; Pruzzo C
Int J Antimicrob Agents; 2011 Feb; 37(2):129-34. PubMed ID: 21163629
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.
Hicks PS; Pelak B; Woods GL; Bartizal KF; Motyl M
Clin Microbiol Infect; 2002 Nov; 8(11):753-7. PubMed ID: 12445016
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
Ulrich M; Berger J; Möller JG; Döring G
Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ciprofloxacin, moxifloxacin, vancomycin and erythromycin against planktonic and biofilm forms of Corynebacterium urealyticum.
Soriano F; Huelves L; Naves P; Rodríguez-Cerrato V; del Prado G; Ruiz V; Ponte C
J Antimicrob Chemother; 2009 Feb; 63(2):353-6. PubMed ID: 19056748
[TBL] [Abstract][Full Text] [Related]
20. Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm.
Wei GX; Campagna AN; Bobek LA
J Antimicrob Chemother; 2006 Jun; 57(6):1100-9. PubMed ID: 16595638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
